Can Johnson & Johnson (JNJ) Break Out to the Upside on Q1 Report?

What's Happening With JNJ View more about JNJ >

Johnson & Johnson (JNJ) will report its first-quarter numbers before the market open April 16. Analysts expect earnings of $2.04 on revenue of $19.63 billion. During the same period last year the company earned $2.06 on sales of $20 billion and the stock is up 5.4% on the year.

Technical Analysis

JNJ was recently trading at $135.99 down $13.00 from its 12-month high and $17.37 above its 12-month low. InvestorsObserver’s Stock Score Report gives JNJ a 68 long-term technical score and a 60 short-term technical score. The stock has recent support above $132.5 and recent resistance below $140. Of the 13 analysts who cover the stock 4 rate it Strong Buy, 2 rate it Buy, 7 rate it Hold, 0 rate it Sell, and 0 rate it Strong Sell, JNJ gets a score of 59 from InvestorsObserver’s Stock Score Report.

Analysts' Thoughts

JNJ took a big hit in December with the overall market correction. Shares did rebound over the first three months of 2019, but profit taking has pushed the stock lower over the last two weeks ahead of this week’s earnings report. JNJ is now trading at 24 times earnings, which is a bit high, but with a forward P/E of 14.8 the stock remains reasonably priced and earnings are expected to rise 6.6% annually over the next five years. JNJ has a strong earnings track record, with better than expected profits every quarter dating back to Q3 2012. If JNJ can extend that streak this quarter the stock should regain its upward momentum. Analysts see additional upside with an average price target of $144.

JNJ
About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, close to half of total revenue is generated in the United States.

  • Last Price:
    $131.75
  • Previous Close:
    $130.11
  • Change:
    $1.64 (1.26%)
  • Open:
    $131.00
  • Volume:
    7,980,602
  • Average Volume (100 Day):
    7,256,788
  • Market Capitalization:
    $347.7 B
  • Day's Range:
    $130.29 - $132.00
  • Dividend Yield:
    2.92%
  • 52-week Range:
    $149 - $121.00
  • P-E:
    21.30
  • EPS:
    $6.03
  • Earnings Date:
    10/15/19
  • Ex Dividend Date:
    8/26/19
  • Sector:
    Healthcare
  • Industry:
    Drug Manufacturers - Major
  • Analyst Average Recommendation:
    Moderate Buy

Already a member?

Login to see your Stocks to Watch Trade Ideas.

Not yet a member?

Receive a Morning Action trade idea every market day in the Morning Update, plus Stocks to Watch Trade Ideas every Saturday.

Become A Member

|